

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10663693	
	Filing Date		2003-09-17	
	First Named Inventor	Evgeny NUDLER et al.		
	Art Unit	1624		
	Examiner Name	Ebenezer O. Sackey		
	Attorney Docket Number	NUDLER2A		

### U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2i</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10663693
Filing Date	2003-09-17
First Named Inventor	Evgeny NUDLER et al.
Art Unit	1624
Examiner Name	Ebenezer O. Sackey
Attorney Docket Number	NUDLER2A

1	IGNARRO, L. J. et al., "Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitro-prusside, and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates", J. Pharmacol. Exp. Ther., Vol. 218, No. 3, pages 739-749 (1981).	<input type="checkbox"/>
2	KEANEY, J.F. Jr, et al., "NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties", J. Clin. Invest. Vol. 91, pages 1582-1589 (1993).	<input type="checkbox"/>
3	CLANCY, R.M., et al., "Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary", Proc. Natl. Acad. Sci. U.S.A., Vol. 91, pages 3680-3684 (1994).	<input type="checkbox"/>
4	GASTON, B., et al., "Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure", Lancet, Vol. 351, pages 1317-1319, (1998).	<input type="checkbox"/>
5	HOGG, N., "Biological chemistry and clinical potential of S-nitrosothiols", Free. Radic. Biol. Med., Vol. 28, No. 10, pages 1478-1486 (2000).	<input type="checkbox"/>
6	AL-SA'DONI, H. et al., "S-Nitrosothiols: a class of nitric oxide-donor drugs", Clin. Sci. (Lond), Vol. 98, pages 507-520 (2000).	<input type="checkbox"/>
7	NAPOLI, et al., "Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis", Proc Natl Acad Sci U S A., Vol. 99, 1689-1694 (2002).	<input type="checkbox"/>
8	SPAHN, D. R., "BLOOD SUBSTITUTES. Artificial oxygen carriers: perfluorocarbon emulsions", Crit. Care, Vol. 3, pages R93-97 (1999).	<input type="checkbox"/>
9	BLANTZ, R.C., et al., "Role of nitric oxide in inflammatory conditions", Nephron, Vol. 90, pages 373-378 (2002).	<input type="checkbox"/>
10	CHABIELSKA, E. et al., "Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats", Thromb Res., Vol. 90, pages 271-278 (1998).	<input type="checkbox"/>
11	SASAKI, N. et al., "Activation of mitochondrial ATP-dependent potassium channels by nitric oxide", Circulation, Vol. 101, pages 439-445 (2000).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10663693
Filing Date	2003-09-17
First Named Inventor	Evgeny NUDLER et al.
Art Unit	1624
Examiner Name	Ebenezer O. Sackey
Attorney Docket Number	NUDLER2A

12	RICHARDSON, et al., "Potential therapeutic uses for S-nitrosothiols". Clin. Sci. (Lond)., Vol. 102, pages 99-105 (2002).	<input type="checkbox"/>
13	GABBAI, "Effects of nitric oxide synthase blockers on renal function", Nephrol. Dial. Transplant., Vol. 16 (Suppl 1), pages 10-13 (2001).	<input type="checkbox"/>
14	HEMMER, K., et al., "An in vitro model for the study of Microglia-Induced Neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha", Neurochem. Int., Vol. 38(7), pages 557-565 (2001). ABSTRACT ONLY	<input type="checkbox"/>
15	LAW, A. et al., "Say NO to Alzheimer's Disease: the putative links between nitric oxide and dementia of the Alzheimer's type", Brain Res. Brain Res. Rev., Vol. 35, No. 1, pages 73-96 (2001). ABSTRACT ONLY	<input type="checkbox"/>
16	DE LA TORRE, J.C. et al., "Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide", Brain Res. Brain Res. Rev., Vol. 34, No. 3, pages 119-136 (2000). ABSTRACT ONLY	<input type="checkbox"/>
17	HARTLAGE-RUBSAMEN, M. et al., "Fibrillary beta-amyloid deposits are closely associated with atrophic nitric oxide synthase (NOS)-expressing neurons but do not upregulate the inducible NOS in transgenic Tg2576 mouse brain with Alzheimer pathology", Neurosci. Lett., Vol. 302, Nos. 2-3, pages 73-76, (2001). ABSTRACT ONLY	<input type="checkbox"/>
18	DAWSON, V. L., et al., "Nitric Oxide Neurotoxicity", J. Chem. Neuroanat., Vol. 10, Nos. 3-4, pages 179-190 (1996). ABSTRACT ONLY	<input type="checkbox"/>
19	SIMONIAN, N. A., et al., "Oxidative stress in neurodegenerative diseases". Annu. Rev. Pharmacol. Toxicol., Vol. 36, pages 83-106 (1996). ABSTRACT ONLY	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Ebenezer Sackey/ (03/12/2009)	Date Considered	
--------------------	--------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.